Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Back to Search
Print
Bookmark Trial

NCT00867087

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Loyola University Medical Center, Foster G. McGraw Hospital and Satellites
Maywood, Illinois, 60153, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
B-Cell Lymphoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- CD20/CD22-positive diffuse large B-cell NHL that has relapsed after 1 or 2 prior therapies; one prior therapy must include anthracyclines and one must include rituximab in combination with chemotherapy

- Relapsed/disease progression within 12 months after start of prior therapy and/or secondary International Prognostic Index (sIPI) score greater than 1

- Eligible for autologous stem cell transplant (aSCT)

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Prior allogeneic hematopoietic stem cell transplant


- Within 6 months prior to test article: autologous transplant, treatment with anti-CD22
antibodies, radio-immunotherapy


- Veno-occlusive disease or sinusoidal obstruction syndrome, chronic liver disease,
systemic vasculitides, current or chronic hepatitis B or C infection

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

B-Cell LymphomaStudy Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL)
NCT00717925
ALL GENDERS
20 Years+
years
MULTIPLE SITES
B-Cell LymphomaStudy Evaluating TRU-015 in B-Cell Non-Hodgkin's Lymphoma
NCT00521638
  1. Duarte, California
  2. San Diego, California
  3. Chicago, Illinois
  4. Boston, Massachusetts
  5. Saint Louis, Missouri
  6. Buffalo, New York
  7. Cleveland, Ohio
ALL GENDERS
18 Years+
years
MULTIPLE SITES
B-Cell LymphomaStudy Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab
NCT00724971
  1. Aichi,
  2. Kanagawa,
  3. Tokyo,
  4. Tokyo,
ALL GENDERS
20 Years+
years
MULTIPLE SITES
B-Cell LymphomaStudy Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma
NCT00867087
  1. Maywood, Illinois
  2. Boston, Massachusetts
  3. Ann Arbor, Michigan
  4. Saint Louis, Missouri
  5. Saint Louis, Missouri
  6. Saint Peters, Missouri
  7. Hackensack, New Jersey
  8. Hackensack, New Jersey
  9. Hackensack, New Jersey
  10. Hackensack, New Jersey
  11. Hackensack, New Jersey
  12. New York, New York
  13. Hershey, Pennsylvania
  14. Dallas, Texas
  15. Dallas, Texas
  16. Dallas, Texas
  17. Houston, Texas
  18. Houston, Texas
  19. San Antonio, Texas
  20. Madison, Wisconsin
  21. Madison, Wisconsin
  22. Lille,
  23. Marseille,
  24. Montpellier Cedex 5,
  25. Paris,
  26. Pessac,
  27. Pierre-Benite cedex 114,
  28. Pierre-benite Cedex,
  29. Strasbourg,
  30. Berlin,
  31. Seoul, Gangnam-gu
  32. Seoul, Seoul/korea
  33. Seoul,
  34. Singapore,
  35. Manchester,
  36. Manchester,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Official Title  ICMJE An Open-label, Single-arm, Phase 2 Study Of Inotuzumab Ozogamicin Plus Rituximab In Subjects With Relapsed/Refractory Cd22-positive Diffuse Large B-cell Lymphoma, Eligible For Autologous Stem Cell Transplantation
Brief Summary The purpose of this study is to evaluate inotuzumab ozogamicin in combination with rituximab prior to an autologous stem cell transplant (aSCT) in patients with relapsed/refractory diffuse large B-cell Non-Hodgkin's lymphoma.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Lymphoma, B-Cell
Intervention  ICMJE
  • Drug: inotuzumab ozogamicin (CMC-544)
    1.8 mg/m^2 every 21 days by intravenous infusion, 3 to 6 doses
    Other Name: cmc-544
  • Drug: rituximab
    375 mg/m^2 two days before cycle 1 by intravenous infusion; 375 mg/m^2 every 21 days by intravenous infusion, 3 to 6 doses
Study Arms  ICMJE Experimental: Rituximab 375 mg/m^2 + Inotuzumab Ozogamicin 1.8 mg/m^2
Inotuzumab ozogamicin, in combination with rituximab, will be administered to patients with relapsed/refractory diffuse large B-cell Non-Hodgkin's lymphoma prior to an autologous stem cell transplant (aSCT).
Interventions:
  • Drug: inotuzumab ozogamicin (CMC-544)
  • Drug: rituximab
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 24, 2017)		64
Original Estimated Enrollment  ICMJE
 (submitted: March 20, 2009)		60
Actual Study Completion Date  ICMJE October 31, 2012
Actual Primary Completion Date October 31, 2012   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • CD20/CD22-positive diffuse large B-cell NHL that has relapsed after 1 or 2 prior therapies; one prior therapy must include anthracyclines and one must include rituximab in combination with chemotherapy
  • Relapsed/disease progression within 12 months after start of prior therapy and/or secondary International Prognostic Index (sIPI) score greater than 1
  • Eligible for autologous stem cell transplant (aSCT)

Exclusion Criteria:

  • Prior allogeneic hematopoietic stem cell transplant
  • Within 6 months prior to test article: autologous transplant, treatment with anti-CD22 antibodies, radio-immunotherapy
  • Veno-occlusive disease or sinusoidal obstruction syndrome, chronic liver disease, systemic vasculitides, current or chronic hepatitis B or C infection
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE France,   Germany,   Korea, Republic of,   Singapore,   United Kingdom,   United States
Removed Location Countries Hong Kong,   Japan,   Mexico,   Poland
 
Administrative Information
NCT Number  ICMJE NCT00867087
Other Study ID Numbers  ICMJE 3129K5-2005
B1931001 ( Other Identifier: Alias Study Number )
2008-007802-12 ( EudraCT Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE UCB Pharma
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date October 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP